Heliad Equity Partners — Portfolio clean up under way

Heliad (XETRA: A7A)

Last close As at 22/04/2024

EUR8.85

0.00 (0.00%)

Market capitalisation

EUR75m

More on this equity

Research: Investment Companies

Heliad Equity Partners — Portfolio clean up under way

Heliad Equity Partners is repositioning its portfolio following the management changes earlier this year. This involves the gradual disposal of holdings in listed companies (with stakes in DEAG Deutsche Entertainment and Cyan already entirely sold) and selected funding measures in non-listed companies (such as Springlane). The company also booked further write-downs on unlisted holdings in H119. The potential acquisition of flatex by a strategic investor at a price ahead of the market value remains Heliad’s key equity driver.

Milosz Papst

Written by

Milosz Papst

Director, Financials

Investment Companies

Heliad Equity Partners

Portfolio clean up under way

Investment companies

Scale research report - Update

16 September 2019

Price

€4.80

Market cap

€47m

Share price graph

Share details

Code

HPBK

Listing

Deutsche Börse Scale

Shares in issue

9.87m

NAV per share at end-June 2019

€6.25

Business description

Heliad Equity Partners is a Germany-based investment company that aims to invest in disruptive companies from the DACH region operating in the technology (fintech, IT security and blockchain) and digital brands sectors. The company is undergoing a restructuring of its legacy investment portfolio.

Bull

The shares trade at a substantial discount to the net asset value.

Potential acquisition of flatex may generate sizeable disposal gains for Heliad.

Recent managerial change may result in improved performance.

Bear

Portfolio concentration: the largest investment comprises more than half of the portfolio.

Early-stage investments inherently higher risk.

The 2.5% management fee paid to a company owned by the main shareholder.

Analyst

Milosz Papst

+44 (0) 20 3077 5700

Heliad Equity Partners is repositioning its portfolio following the management changes earlier this year. This involves the gradual disposal of holdings in listed companies (with stakes in DEAG Deutsche Entertainment and Cyan already entirely sold) and selected funding measures in non-listed companies (such as Springlane). The company also booked further write-downs on unlisted holdings in H119. The potential acquisition of flatex by a strategic investor at a price ahead of the market value remains Heliad’s key equity driver.

In the black due to higher flatex’s share price

Heliad’s H119 net profit reached a minor €0.4m (compared to a significant loss of €15.8m in H118), which was mainly assisted by the share price appreciation in its largest holding flatex (representing c 61% of NAV at end-June 2019). In contrast, it booked €2.4m write-downs on unlisted holdings (in particular Muume and Libify). Consequently, its net valuation gain reached €1.6m in H119 (vs a €12.3m loss in H118). At the same time, Heliad reported a minor net disposal loss at €0.2m vs a €0.6m gain in H118.

Shift away from listed holdings

Heliad intends to focus on investments in unlisted holdings across various industries, with a possible emphasis on the fintech, IT and security, blockchain and digital brands sectors. We note that this would represent some overlap with FinLab’s investment strategy, which is Heliad’s main shareholder and whose board members recently replaced the previous board at Heliad. As the company exits its listed holdings and redeploys the proceeds, we expect its portfolio may start to resemble FinLab’s at some stage, which may encourage the owners to merge the entities. We note that although Heliad may retain its stake in flatex in the short term, it may decide to sell it in the case of an offer from a strategic investor.

Valuation: Still trading at a sizeable discount to NAV

Heliad trades at a 23% discount to last reported NAV per share at end-June 2019 of €6.25. After the balance sheet date, the shares in its largest listed holding (flatex) went up by c 45%, driven by acquisition rumours and good financial results. Taking into account movements in Magforce and Elumeo shares after end-June 2019 and adjusting Heliad’s NAV for the change in the share price of all three listed holdings, we estimate Heliad is trading at a 39% discount to NAV.

Historical financials

Year
end

Net revenue
(€m)

PBT

(€m)

EPS

(€)

P/E
(x)

NAV/share

(€)

P/NAV
(x)

12/15

29.2

23.0

2.4

2.0

10.9

0.4

12/16

(16.6)

(22.2)

(2.3)

N/A

8.4

0.6

12/17

43.1

39.6

4.0

1.2

12.2

0.4

12/18

(50.6)

(57.6)

(5.7)

N/A

6.2

0.8

Source: Heliad Equity Partners. Note: P/NAV based on current share price.

Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.

H119 results: Assisted by flatex revaluation

Heliad’s net income reached €0.4m in H119 compared with a net loss of €15.8m in H118. This was largely a function of the net revaluation gain, which stood at €1.6m in H119 versus a net loss of €12.3m in H118. Based on our estimates, we believe the main positive contributor was flatex (formerly Fintech Group), Heliad’s largest portfolio holding with a c 61% share in its NAV at end-June 2019 (54% at end-2018). flatex’s share price increased c 14% in H119, translating into a c €4.6m valuation impact. This was partially offset by the write-downs of non-listed holdings at €2.4m in H119 (none booked in H118). Based on our conversation with the company, we understand this was associated primarily with Muume and Libify. An additional minor negative contribution came from Elumeo’s share price decline of c 40% in H119. Last year, Heliad’s results were burdened by the fall in the share price of nearly all listed portfolio holdings, reflecting the broader conditions in equity markets.

The company reported a minor net disposal loss of €0.2m in H119 compared with an €0.6m gain in H118. During the period, the company reduced its holdings in all listed companies (except Elumeo), including flatex, MagForce, Cyan, Max21 and DEAG Deutsche Entertainment. We understand this is part of Heliad’s repositioning process, as it intends to focus on private investments (see our discussion below). We understand the stakes in Cyan and DEAG were sold completely in H119. At the same time, Heliad’s holding in flatex was reduced to 9.9% at end-June 2019 from 10.9% at end-2018. Consequently, Heliad held stakes in three listed companies at end-June 2019: flatex, MagForce and Elumeo.

Other operating expenses declined visibly to €1.4m from €4.6m in H118, largely supported by lower costs of management and liability at €0.9m vs €2.6m in H118 associated with fees paid to Heliad Asset Management (Heliad’s investment manager), as well as reduced expenses for bad debt allowances (€0.1m vs €1.4m in H118). As a result, diluted EPS was €0.04 after a loss per share of €1.59 was recorded in H118.

Exhibit 1: H119 results highlights

€000s, unless otherwise stated

H119

H118

y-o-y change

Income from the sale of financial assets

5,109

12,887

-60.4%

Other operating income

0

13

N/M

Gains from revaluation

4,908

614

N/M

Retirement of financial assets

(5,275)

(12,285)

-57.1%

Depreciation of intangible assets

(2)

(2)

0.0%

Income from investments

11

0

N/M

Depreciation of financial assets

(3,270)

(12,877)

-74.6%

Financial revenue

354

134

N/M

Financial expenses

(7)

(37)

N/M

Other operating expenses

(1,391)

(4,588)

-69.7%

Pre-tax profit

438

(16,140)

N/M

Income taxes

(52)

369

N/M

Net profit

386

(15,771)

N/M

Average number of shares (diluted)

9,873

9,941

-0.7%

EPS (diluted, €)

0.04

(1.59)

N/M

Source: Heliad Equity Partners

Heliad’s NAV per share decreased c 40% to €6.25 at end-June 2019 vs end-June 2018 (€10.38) as a result of negative valuation effects related to both listed and unlisted holdings (for more details see our previous two update notes). That said, it remained broadly stable compared to end-2018 NAV at €6.20 per share due to the factors described above.

Reorientation to focus on innovative private companies

Following management changes in April 2019 associated with Heliad’s weak FY18 results, the company has been in restructuring mode. Stefan Schütze and Juan Rodriguez (two board members of Heliad’s largest shareholder, FinLab, who replaced the previous CEO) will remain on Heliad’s management board and will focus on maximising the value of the existing portfolio while exploring opportunistic investments across different industries, with a potential stronger emphasis on the fintech, IT security, blockchain and digital brand sectors. We understand that Heliad will seek new private investments rather than invest in listed holdings (which are easily accessible directly for Heliad’s investors at a lower cost).

Although we believe Heliad may retain its c 9.9% stake in flatex (at least in the short term), we also acknowledge that flatex recently initiated a review of strategic options, including a potential sale of the business and onboarding of new investors. This could potentially represent an exit route for Heliad and (depending on the attractiveness of the actual exit price) might translate into a significant disposal gain. In the longer term, Heliad’s investment activity should become more aligned with FinLab’s approach and, in our opinion, it is possible the two entities might be merged at some stage.

Recent portfolio developments

Heliad’s current portfolio is a combination of holdings in listed companies and privately held investments. The former includes flatex (an integrated online brokerage business), MagForce (a biotech player with approved nanotechnology-based therapy to treat brain cancer) and Elumeo (an online jewellery retailer with relatively weak recent performance). Heliad holds stakes in six non-listed companies: Springlane, Spaze, Alphapet, Libify, Muume and Tiani Spirit.

We note that Heliad’s NAV per share and financial results are mainly dependent on the share price development of flatex. Following this holding’s c 45% share price appreciation since end-June 2019 (triggered by the strategic review and H119 results), Heliad’s 9.9% stake in the company is worth c €54.4m compared with €37.4m at end-June 2019. In addition, flatex raised its FY19 EBITDA margin target in July 2019 to 31% from 29% on the back of solid preliminary H119 figures and the ongoing product rollout in the Netherlands. In H119, the company posted a c 10% y-o-y increase in sales to €64.3m and EBITDA at €19.7m, up c 7% y-o-y. flatex states that lower market volatility in H119 was more than offset by a dynamic expansion of its customer base. As announced in August 2019, the company attracted c 32k new customers in the year to date (including almost 10k in the Netherlands), which is already in line with the whole of 2018. It also reiterated its plan of attracting 60,000 new customers in 2019.

Magforce is making progress with its strategy to drive the uptake of its thermal ablation treatment, NanoTherm. It recently announced it has completed treatment of the first 10-patient cohort in the pivotal prostate cancer study required by the US FDA for approval. It has indicated that the initial findings from this first cohort indicate treatment side effects have been minimal and in line with that of biopsies. See our recent notes for more details.

With respect to Heliad’s unlisted holdings, we note that Springlane (a retailer of kitchenware) closed a €10m financing round in August 2019. The funds received from Apeiron Investment Group, S-UBG Group and existing shareholders will be used to finance the company’s growth. Following the funding round, Heliad continues to be Springlane’s largest shareholder with a 26.5% stake.

Valuation

Heliad assesses its own NAV per share on the basis of the market valuation of listed holdings and valuation of unlisted holdings based on new funding rounds or secondary transactions. The company is trading at a 23% discount to the last published NAV per share of €6.25. Movements in the discount between publication of the quarterly NAV tend to reflect the valuation of listed holdings, which we estimate made up c 70% of NAV (c 61% for flatex alone) at end-June 2019. We estimate that flatex’s c 45% share price increase since end-June 2019 translates into an incremental NAV per share improvement of c 28% (or c €1.72 per Heliad share). The net negative impact of share price changes in Heliad’s remaining two listed holdings (Magforce and Elumeo) might have resulted in an NAV deterioration of c €0.05 per Heliad share, according to our estimates. Adding the net figure (c €1.67) to Heliad’s last reported NAV per share suggests the underlying discount may now be closer to 39%. This means Heliad’s current market capitalisation is below the market value of its stake in flatex. However, we believe the discount to NAV might partially reflect Heliad’s recent poor performance.

Exhibit 2: Heliad’s NAV and share price performance

Exhibit 3: Heliad’s discount to NAV

Source: Heliad Equity Partners

Source: Heliad Equity Partners, Edison Investment Research

Exhibit 2: Heliad’s NAV and share price performance

Source: Heliad Equity Partners

Exhibit 3: Heliad’s discount to NAV

Source: Heliad Equity Partners, Edison Investment Research

General disclaimer and copyright

Any Information, data, analysis and opinions contained in this report do not constitute investment advice by Deutsche Börse AG or the Frankfurter Wertpapierbörse. Any investment decision should be solely based on a securities offering document or another document containing all information required to make such an investment decision, including risk factors. This report has been commissioned by Deutsche Börse AG and prepared and issued by Edison for publication globally.

Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2019 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited (“FTSE”) © FTSE 2019. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

The Investment Research is a publication distributed in the United States by Edison Investment Research, Inc. Edison Investment Research, Inc. is registered as an investment adviser with the Securities and Exchange Commission. Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1,185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Heliad

View All

Investment Companies

Heliad — Starting a new chapter

Investment Companies

Heliad Equity Partners — Plans to merge with FinLab

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

Onxeo — Next generation of DNA damage repair inhibitors

Onxeo is focused on the development of the next generation of DNA damage repair inhibitors from its novel oligonucleotide platON platform. The lead asset, AsiDNA, belongs to the same class of drugs as PARP inhibitors, but has a different mechanism of action. AsiDNA is in a Phase Ib trial in combination with chemotherapy in solid tumours; preliminary results are expected by end-2019, which is within the existing cash reach to Q320. To reflect the progress Onxeo has made with AsiDNA we have included the second indication for this asset in our valuation, but removed some of the legacy projects. Our updated valuation is €129m or €2.3/share.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free